New animal research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide treatment, with tirzepatide temporarily increasing energy expenditure and semaglutide initially reducing energy expenditure.